| Similar Articles |
|---|
 |
The Motley Fool
November 11, 2008
Brian Orelli |
Two Years of Red Aesthetic laser makers have been rocked over the last few years.   |
The Motley Fool
May 15, 2008
Brian Orelli |
So-So Syneron A little growth is an acceptable outcome in the struggling medical laser industry. |
The Motley Fool
September 22, 2008
Brian Orelli |
Syneron Irons Out Some Wrinkles The aesthetic device maker gets a new product approved in Europe. |
The Motley Fool
May 15, 2006
Stephen D. Simpson |
Sales and Marketing Slam Syneron Higher expenses and disappointing results leave the med-tech stock suffering. |
The Motley Fool
June 14, 2005
Stephen D. Simpson |
Syneron Aims for Cellulite An FDA approval gives Israel's Syneron the lead in non-surgical cellulite treatment. With robust profit margins, that additional revenue could make a big impact on the bottom line. Investors, take note. |
The Motley Fool
May 8, 2007
Rich Duprey |
Cutera's Ugly Quarter The aesthetic laser maker's weak domestic sales dim the outlook for the rest of the year. Investors, take note. |
The Motley Fool
February 4, 2008
Kristin Graham |
Best International Stock: Syneron Medical A quick summary of Israeli medical device maker Syneron, a company that could keep you and your portfolio both looking young and healthy. |
The Motley Fool
April 30, 2007
Rich Duprey |
Foolish Forecast: Cutera Zaps Quarter Investors, don't expect the aesthetic laser maker to burn up the growth charts when it reports first-quarter results. |
The Motley Fool
December 7, 2006
Matt Koppenheffer |
The Best Small Cap for 2007: Syneron This Israel-based aesthetic laser company has financials that need no cosmetic touch-ups. Investors, take note. |
The Motley Fool
April 24, 2008
Rich Duprey |
Candela Fizzles Aesthetic laser maker Candela reports slightly higher revenue but wider-than-anticipated losses. |
The Motley Fool
April 10, 2007
Rich Duprey |
The Beauty of Lasers With aesthetic laser treatments booming, which company looks the best? Candela... Cutera... Palomar Medical Technologies... Cynosure... Syneron... |
The Motley Fool
February 13, 2007
Rich Duprey |
Palomar's Parallax View A plethora of one-time revenues skewed the aesthetic laser maker's results. Investors, take note. |
The Motley Fool
September 10, 2007
Rich Duprey |
A Strategic Alternative for Candela In an SEC filing, hedge fund Third Point LLC reports its discussions of "strategic alternatives" at laser maker Candela. Some say a sale was discussed. Investors should take notice. |
The Motley Fool
February 13, 2006
Stephen D. Simpson |
Will Syneron Defy History? Publicly traded laser companies have a legacy of failure; will Syneron manage to turn that tide? |
The Motley Fool
March 14, 2008
Rich Duprey |
No Point Man at Candela Activist hedge fund Third Point cuts its stake in the aesthetic laser maker Candela from 9% to only 3.5%. |
The Motley Fool
April 25, 2007
Rich Duprey |
Candela's Amazing Shrinking Quarter The aesthetic laser maker reports its second consecutive quarter of declining sales. Investors, take note. |
The Motley Fool
February 28, 2007
Matt Koppenheffer |
P&G to Help Syneron Smooth Its Customers The consumer-goods giant teams up with the small cap to treat consumers' skin. The real question for investors, though, is how these new products will impact the company's financials. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
Laser Beamer Lookin' Good Palomar continues to build a profitable business in the highly competitive cosmetic laser market. |
The Motley Fool
May 12, 2006
Rich Duprey |
Cutera Continues to Burn The aesthetic laser maker is at risk of losing a patent lawsuit against a competitor. Investors, patents by themselves should not be considered a sufficient competitive moat to induce investment in a company. |
The Motley Fool
February 14, 2006
Rich Duprey |
Cutera's Laser Woes Aesthetic laser maker has a cloudy future of lower sales, earnings, and patent lawsuits. Investors, take note. |
The Motley Fool
April 9, 2007
Rich Duprey |
Cutera's Meltdown The maker of aesthetic lasers lowers guidance, and Mr. Market's reaction isn't surprising. |
The Motley Fool
January 10, 2006
Rich Duprey |
Biolase Brightens Outlook The aesthetic laser company expects to be cash flow-neutral on flat revenues. Investors cheer. |
The Motley Fool
May 2, 2007
Rich Duprey |
Cynosure Sure Looks Good Aesthetic-laser maker reports record results on strength of new laser offerings. Investors, take note. |
The Motley Fool
January 31, 2008
Rich Duprey |
Candela Investors Burned Again The aesthetic-laser maker continues its string of disappointing quarters. |
The Motley Fool
July 30, 2007
Brian Orelli |
Palomar Plummets In the second quarter, cosmetic-laser maker Palomar Medical Technology had a stellar performance in the former, but investors couldn't look past the lack of royalty payments. |
The Motley Fool
October 26, 2006
Rich Duprey |
Candela's October Surprise The aesthetic laser maker trounces analyst projections, though all may not be what it seems. Investors, take note. |
The Motley Fool
April 3, 2007
Rich Duprey |
Palomar Medical Burns Another Rival The aesthetic laser maker zaps a privately held firm for patent infringement. But one company not buckling under to Palomar's aggressive tactics is Candela. Investors, take note. |
The Motley Fool
September 27, 2007
Brian D. Pacampara |
5 More Turnaround Stocks These companies may be poised for turnarounds: Alberto-Culver, ACI Worldwide, Palomar Medical Technologies, Carter's, and Aspreva Pharmaceuticals. Investors should consider, but with caution. |
The Motley Fool
May 22, 2006
Rich Duprey |
A Change of Heart for Candela An upgrade of the laser maker points out the futility of watching analysts' shifting opinions. One of the tricks to generating long-term profits is to ignore the shifting winds of analyst sentiment and focus solely on the ability of the company to deliver. |
The Motley Fool
December 14, 2005
Stephen D. Simpson |
An Ugly Battle in Aesthetics Palomar Medical Tech scores an initial win over Cutera in an intellectual property battle, but the war isn't over yet. Investors, take note. |
The Motley Fool
January 12, 2009
Brian Orelli |
Abbott Eyes New Growth Abbott announces it's buying eye-care specialist Advanced Medical Optics for $22 per share -- nearly 150% higher than Friday's close on the stock. |
